報價延遲最少15分鐘:2025/06/18 10:56 EDT
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.6172 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-24.00/-31.00
|
|
企業價值
726.03M
|
| 資產負債 |
|
每股賬面淨值
-5.05
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
170.00K
|
|
每股收益
0.00
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
報價延遲最少15分鐘：2025/06/18 10:56 EDT
同行比較之報價最少15分鐘延遲
|
業務概覽
|
|||
| AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS). |